Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score

BJU International

Volumn 110, Issue 11 B, 2012, Pages

  De Luca, Stefano ^a   Passera, Roberto ^b   Milillo, Angela ^b   Coda, Renato ^b   Randone, Donato Franco ^a  

^a GRADENIGO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

High grade prostate intra epithelial neoplasia; Prostate cancer; Prostate cancer antigen 3 gene; Prostate specific antigen; Prostatitis

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CHRONIC PROSTATITIS; CONTROLLED STUDY; DIAGNOSTIC TEST; ETHNIC GROUP; HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER GENE 3; PROSTATE CANCER GENE 3 SCORE; PROSTATE CANCER GENE 3 TEST; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SCORING SYSTEM; TUMOR GENE; CHRONIC DISEASE; COMPARATIVE STUDY; NEEDLE BIOPSY; PATHOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROSTATE TUMOR; PROSTATITIS; RECEIVER OPERATING CHARACTERISTIC; URINE;

ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; CHRONIC DISEASE; HUMANS; ITALY; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS; ROC CURVE;

MLCS; MLOWN;

EID: 84876436635     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11645.x     Document Type: Article

References (32)

1. Bussemakers MJ, van Bokhoven A, Verhaegh GW et al. A new prostatespecific gene, highly over expressed in prostate cancer. Cancer Res 1999; 59: 5975-9
2. Hessels D, Klein Gunnewiek JM, van Oort I et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-15
3. de Kok JB, Verhaegh GW, Roelofs RW et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 695-8
4. Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancerspecific gene. Urology 2003; 62: 34-43
5. Haese A, de la Taille A, van Poppel H et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-8
6. Groskopf J, Aubin SM, Deras IL et al. Aptima PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089-95
7. Deras IL, Aubin SM, Blase A et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587-92
8. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine. A new perspective for detecting prostate cancer. Eur Urol 2004; 46: 182-6
9. Vlaeminck-Guillem V, Bandel M, Cottancin M, Rodriguez-Lafrasse C, Bohbot JM, Sednaoui P. Chronic prostatitis does not influence urinary PCA3 score. Prostate 2012; 72: 549-54
10. Ferro M, Bruzzese D, Perdonà S et al. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta 2012; 413: 1274-8
11. Roobol MJ. Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Curr Opin Urol 2011; 21: 225-9
12. Postma R, Schroder FH, van der Kwast TH. Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men. Urology 2005; 65: 745-9
13. Kryvenko ON, Jankowski M, Chitale DA et al. Inflammation and preneoplastic lesions in bening prostate as risk factors for prostate cancer. Mod Pathol 2012; 25: 1023-32
14. Murphy AB, Macejco A, Taylor A, Nadler RB. Chronic prostatitis: management strategies. Drugs 2009; 69: 71-84
15. Habermaker GM, Chason JT, Shaeffer AJ. Prostatitis/chronic pelvic pain syndrome. Annu Rev Med 2006; 57: 195-206
16. De Marzo AM, Platz EA, Sutcliffe S. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-69
17. MacLennan GT, Eisenberg R, Fleshman RL. The influence of chronic inflammation in prostatic carcinogenesis: a 5 year followup study. J Urol 2006; 176: 1012-6
18. Terakawa T, Miyake H, Kanomata N. Inverse association between histological inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/ml. Urology 2008; 72: 1194-7
19. Schatteman PH, Hoekx L, Wyndaele JJ. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 2000; 37: 404-12
20. Bostwick DG, Cheng L. Precursors of prostate cancer. Histopathology 2012; 60: 4-27
21. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006; 175: 820-34
22. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 2004; 17: 360-79
23. Greene KL, Albertsen PC, Babaian RJ et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009; 182: 2232-41
24. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452-5
25. Auprich M, Haese A, Walz J et al. External validation of urinary PCA3- based nomograms to individually predict prostate biopsy outcome. Eur Urol 2010; 58: 727-32
26. Ploussard G, Durand X, Xylinas E et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011; 59: 422-9
27. de la Taille A, Irani J, Graefen M et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 2011; 185: 2119-25
28. Bollito E, De Luca S, Cicilano M et al. Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer. A validation study on an itaian population undergoing first and repeat biopsy. Anal Quant Cytol Histol 2012; 34: 96-104
29. Wang R, Chinnayan AM, Dunn RL, Wojno KJ, Wei JT. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 2009; 115: 3879-86
30. Laurila M, van der Kwast T, Bubendorf L et al. Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer. Eur J Cancer 2010; 46: 3068-72
31. Morote J, Rigau M, Garcia M. Behavior of the PCA3 gene in the urine of men with high-grade prostatic intraepithelial neoplasia. World J Urol 2010; 28: 677-80
32. Roobol MJ, Schröder FH, van Leenders GL et al. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100). Eur Urol 2010; 58: 893-9